Anhco Nguyen Sells 5,062 Shares of Atara Biotherapeutics (NASDAQ:ATRA) Stock

Key Points

• CEO Anhco Nguyen sold 5,062 Atara Biotherapeutics shares at an average price of $8.08, totaling approximately $40,901. The sale covered tax withholding obligations tied to vested equity awards and reduced his holdings by 3.67%.
• Atara’s shares recently traded at $9.38, with the company valued at about $94.2 million. Its latest quarterly loss of $0.32 per share matched estimates, while revenue of $0.63 million exceeded forecasts.
• Analyst sentiment is mixed but leans positive, with a consensus “Moderate Buy” rating and an average price target of $9.50. Institutional investors own approximately 70.9% of the company’s stock.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) CEO Anhco Nguyen sold 5,062 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $8.08, for a total transaction of $40,900.96. Following the sale, the chief executive officer directly owned 132,775 shares in the company, valued at approximately $1,072,822. This represents a 3.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Atara Biotherapeutics Price Performance

Shares of NASDAQ ATRA traded down $0.46 during midday trading on Wednesday, hitting $9.38. The stock had a trading volume of 63,701 shares, compared to its average volume of 50,209. The firm has a market cap of $94.18 million, a P/E ratio of -7.95 and a beta of 0.12. Atara Biotherapeutics, Inc. has a fifty-two week low of $3.92 and a fifty-two week high of $19.15. The company's 50-day simple moving average is $9.30 and its 200 day simple moving average is $7.54.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.32). The business had revenue of $0.63 million for the quarter, compared to analyst estimates of $0.55 million. Atara Biotherapeutics had a negative return on equity of 79.12% and a negative net margin of 269.42%. Equities analysts expect that Atara Biotherapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ATRA shares. Canaccord Genuity Group set a $13.00 target price on shares of Atara Biotherapeutics and gave the company a "buy" rating in a research note on Friday, May 8th. TD Cowen raised shares of Atara Biotherapeutics to a "strong-buy" rating in a research note on Monday. Wall Street Zen upgraded shares of Atara Biotherapeutics from a "sell" rating to a "hold" rating in a report on Sunday, August 16th. Freedom Capital raised shares of Atara Biotherapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday, May 18th. Finally, Weiss Ratings raised shares of Atara Biotherapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Atara Biotherapeutics has a consensus rating of "Moderate Buy" and an average price target of $9.50.

Hedge Funds Weigh In On Atara Biotherapeutics

Several institutional investors have recently modified their holdings of the business. Globeflex Capital L P raised its holdings in Atara Biotherapeutics by 399.6% during the 4th quarter. Globeflex Capital L P now owns 77,224 shares of the biotechnology company's stock worth $1,397,000 after buying an additional 61,766 shares during the period. Bridgeway Capital Management LLC raised its holdings in shares of Atara Biotherapeutics by 133.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 32,691 shares of the biotechnology company's stock worth $591,000 after acquiring an additional 18,691 shares during the period. Marshall Wace LLP lifted its position in Atara Biotherapeutics by 28.4% in the 4th quarter. Marshall Wace LLP now owns 148,632 shares of the biotechnology company's stock valued at $2,689,000 after acquiring an additional 32,836 shares in the last quarter. Renaissance Technologies LLC lifted its position in Atara Biotherapeutics by 58.6% in the 4th quarter. Renaissance Technologies LLC now owns 30,040 shares of the biotechnology company's stock valued at $543,000 after acquiring an additional 11,104 shares in the last quarter. Finally, Mackenzie Financial Corp boosted its stake in Atara Biotherapeutics by 183.5% in the 3rd quarter. Mackenzie Financial Corp now owns 63,816 shares of the biotechnology company's stock worth $914,000 after purchasing an additional 41,302 shares during the period. Institutional investors own 70.90% of the company's stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company's lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source